Zygomycosis: An emerging fungal infection with new options for management

Current Infectious Disease Reports

Volumn 9, Issue 6, 2007, Pages 435-440

  Kauffman, Carol A ^a   Malani, Anurag N ^b  

^a VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; ECHINOCANDIN; FLUCYTOSINE; OXYGEN; POSACONAZOLE; TERBINAFINE; VORICONAZOLE;

CHEMOPROPHYLAXIS; CLINICAL FEATURE; CLINICAL TRIAL; DEBRIDEMENT; DIABETES MELLITUS; DIABETIC PATIENT; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG USE; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERBARIC OXYGEN; IMMUNOCOMPROMISED PATIENT; INFECTION RISK; LUNG INFECTION; MAXIMUM PERMISSIBLE DOSE; MUCORMYCOSIS; NEPHROTOXICITY; NOTE; RISK FACTOR;

EID: 36049030248     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-007-0066-4     Document Type: Note

References (49)

1. Ribes JA, Vanover-Sams CL, Baker DJ: Zygomycetes in human disease. Clin Microbiol Rev 2000, 13:236-301.
2. Spellberg B, Edwards J, Ibrahim A: Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005, 18:556-569.
3. Gomez-Lopez A, Cuenca-Estrella M, Monzon A, Rodriquez-Tudela JL: In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole, and voriconazole. J Antimicrob Chemother 2001, 48:919-921.
4. Sun QN, Fothergill AW, McCarthy DI, et al.: In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002, 46:1581-1582.
5. Torres-Narbona M, Guiniea J, Martinez-Alarcon J, et al.: In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensitive YeastOne, and the E test. Antimicrob Agents Chemother 2007, 51:1126-1129.
6. Andresen D, Donaldson A, Choo L, et al.: Multifocal cutaneous mucormycosis complicating polymicrobial wound infections in a tsunami survivor from Sri Lanka. Lancet 2005, 365:876-878.
7. Oliver MR, Van Voorhis WC, Boeckh M, et al.: Hepatic mucormycosis in a bone marrow transplant recipient who ingested naturopathic medicine. Clin Infect Dis 1996, 22:521-524.
8. Roden MM, Zaoutis TE, Buchanan WL, et al.: Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005, 41:634-653.
9. Baddley JW, Stroud TP, Salzman D, Pappas PG: Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001, 32:1319-1324.
10. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV: Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000, 30:851-856.
11. Almyroudis NG, Sutton DA, Linden P, et al.: Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant 2006, 6:2365-2374.
12. Kontoyiannis DG: Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis. Clin Infect Dis 2007, 44:1089-1090.
13. Chakrabarti A, Das A, Mandal J, et al.: The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol 2006, 44:335-342.
14. Boelaert JR, van Roost GF, Verqauwe PL, et al.: The role of desferrioxamine in dialysis-associated myucormycosis: report of three cases and review of the literature. Clin Nephrol 1988, 29:261-266.
15. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al.: Invasive zygomycosis in hematopoietic stem-cell transplant patients receiving voriconazole prophylaxis. Clin Infect Dis 2004, 39:584-587.
16. Marty FM, Cosimi LA, Baden LR: Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem cell transplants. N Engl J Med 2004, 350:950-952.
17. Imhof A, Balajee SA, Fredricks DN, et al.: Breakthrough fungal infections in stem cell transplant patients receiving voriconazole. Clin Infect Dis 2004, 39:743-746.
18. Vigouroux S, Morin O, Moreau P, et al.: Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematological disease: attention required. Clin Infect Dis 2005, 40:e35-37.
19. Kobayashi K, Kami M, Murashige N, et al.: Breakthrough zygomycosis during voriconazole treatment for invasive aspergillosis. Haematologica 2004, 89:ECR42.
20. Oren I: Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis 2005, 40:770-771.
21. Trifilio SM, Bennett CL, Yarnold PR, et al.: Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007, 39:425-429.
22. Kontoyiannis DP, Lionakis MS, Lewis RE, et al.: Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005, 191:1350-1360.
23. Prabhu RM, Patel R: Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004, 10(Suppl 1):31-47.
24. Hopkins RJ, Rothman M, Fiore A, Goldblum SE: Cerebral mucormycosis associated with intravenous drug use: three case reports and review. Clin Infect Dis 1994, 19:1133-1137.
25. Chamilos G, Marom EM, Lewis RE, et al.: Predictors of pulmonary zygomycosis versus pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005, 41:60-66.
26. Adams RD, Hunter G, DiTomasso J, Comerci G: Mucormycosis: emerging prominence of cutaneous infections. Clin Infect Dis 1994, 19:67-76.
27. Agha FP, Lee HH, Boland CR, Bradley SF: Mucormycoma of the colon: early diagnosis and successful management. Am J Roentgenol 1985, 145:739-741.
28. Padmanabhan S, Battiwalla M, Hahn T, et al.: Two cases of hepatic zygomycosis in allogeneic stem cell transplant recipients and review of literature. Transpl Infect Dis 2007, 9:148-152.
29. Rinaldi MG: Zygomycosis. Infect Dis Clin N Am 1989, 3:19-41.
30. Kontoyiannis DP, Chamilos G, Lewis RE, Tarrand JJ: Increased culture recovery of zygomycetes under physiologic temperatuire conditions [abstract #279]. Presented at the 43rd Annual Meeting of the Infectious Diseases Society of America. San Francisco, CA; October 6-9, 2005.
31. Schwarz P, Bretagne S, Gantier JC, et al.: Molecular identification of Zygomycetes from culture and experimentally infected tissues. J Clin Microbiol 2006, 44:340-349.
32. Perfect JR: Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis 2005, 40:s401-s408.
33. Herbrecht R, Letscher-Bru V, Bowden RA, et al.: Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis 2001, 20:460-466.
34. Forrest GN, Mankes K: Outcomes of invasive zygomycosis infections in renal transplant recipients. Transpl Infect Dis 2007, 9:161-164.
35. Torres HA, Hachem RY, Chemaly RF, et al.: Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005, 5:775-785.
36. Greenberg RN, Mullane K, van Burik JA, et al.: Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006, 50:126-133.
37. Tobon AM, Arango M, Fernandez D, Restrepo A: Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin Infect Dis 2003; 36:1488-1491.
38. van Burik JA, Hare RS, Solomon HF, et al.: Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006, 42:e61-e65.
39. Sansone-Parsons A, Krishna G, Calzetta A, et al.: Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother 2006, 50:1881-1883.
40. Ullmann AJ, Cornely OA, Burchardt A, et al.: Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006, 50:658-666.
41. Dannaoui E, Afeltra J, Meis JF, et al.: In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. Antimicrob Agents Chemother 2002, 46:2708-2711.
42. Voitl P, Scheibenpflug C, Weber T, et al.: Combined antifungal treatment of visceral mucormycosis with caspofungin and liposomal amphotericin B. Eur J Clin Microbiol Infect Dis 2002, 21:632-634.
43. Spellberg B, Fu Y, Edwards JE, Ibrahim AS: Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother 2005, 49:830-832.
44. Reed C, Ibrahim A, Edwards JE Jr, et al.: Deferasirox, an iron chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 2006, 50:3968-3969.
45. Sahin B, Paydas S, Cosar E, et al.: Role of granulocyte colony-stimulating factor in the treatment of mucormycosis. Eur J Clin Microbiol Infect Dis 1996, 15:866-869.
46. Garcia-Diaz JB, Palau L, Pankey GA: Resolution of rhinocerebral zygomycosis associated with adjuvant administration of granulocyte-macrophage colony-stimulating factor. Clin Infect Dis 2001, 32:e145-e150.
47. Ferguson BJ, Mitchell TG, Moon R, et al.: Adjunctive hyperbaric oxygen for treatment of rhinocerebral mucormycosis. Rev Infect Dis 1988, 10:551-559.
48. John BV, Chamilos G, Kontoyiannis DP: Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin Microbiol Infect 2005, 11:515-517.
49. Ibrahim AS, Edwards JE Jr, Fu Y, et al.: Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother 2006, 58:1070-1073.